
During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
A 50-Year-Old Woman With ALK-Rearranged NSCLC
Case: A 50-Year-Old Woman WithALK-Rearranged NSCLC



